A recent collaborative study published by Amgen and Kite Pharma cites the use of HemaCare sourced peripheral blood mononuclear cells (PBMC) in their investigative effort on the development of a novel CAR T cell therapy. [1]
Acute myeloid leukemia (AML) is a form of blood cancer characterized by the rapid buildup of abnormal cells in the bone marrow. The disease affects about a million people globally and, tragically, has a less than 30% survival rate.